





WHAT IS CLAIMED IS:

1. A compound represented by Formula (I), (II), (III) or (IV):




or



or a pharmaceutically acceptable salt thereof, wherein

HET is one of the following heterocycles:



5 R^1 is

(a) H;

(b) C_1 - C_6 -alkyl, C_2 - C_4 -alkenyl, C_2 - C_4 -alkynyl, C_3 - C_6 -cycloalkyl, or C_1 - C_4 -alkyl- $[C_3$ - C_6 -cycloalkyl], any of which is optionally substituted with one or more of the following substituents: F, CF_3 , OH, O- $(C_1$ - C_4)alkyl, $S(O)_{0-2}$ - $(C_1$ - C_4)alkyl, O- $CONR^aR^b$, NR^aR^b , $N(R^a)CONR^aR^b$, COO - $(C_1$ - C_4)alkyl, $COOH$,
10 CN , $CONR^aR^b$, $SO_2NR^aR^b$, $N(R^a)SO_2NR^aR^b$, $-C(=NH)NH_2$, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl;

(c) $-O$ - C_1 - C_6 -alkyl, $-O$ - C_3 - C_6 -cycloalkyl, $-S$ - C_1 - C_6 -alkyl or $-S$ - C_3 - C_6 -cycloalkyl, any of which is optionally substituted with one or more of the following substituents: F, CF_3 , OH, O- $(C_1$ - C_4)alkyl, $S(O)_{0-2}$ - $(C_1$ - C_4)alkyl, O- $CONR^aR^b$, NR^aR^b , $N(R^a)CONR^aR^b$, COO - $(C_1$ - C_4)alkyl, $COOH$, CN ,
15 $CONR^aR^b$, $SO_2NR^aR^b$, $N(R^a)SO_2NR^aR^b$, $-C(=NH)NH_2$, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl;

(d) $-C_0$ - C_4 -alkyl- C_1 - C_4 -perfluoroalkyl, or $-O$ - C_0 - C_4 -alkyl- C_1 - C_4 -perfluoroalkyl;

20 (e) $-OH$;

(f) $-O$ -aryl, or $-O$ - C_1 - C_4 -alkyl-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) $-CN$, iii) $-NO_2$, iv) $-C(=O)(R^a)$, v) $-OR^a$, vi) $-NR^aR^b$, vii) $-C_0$ -4alkyl- CO - OR^a , viii) $-(C_0$ -4alkyl)- NH - CO - OR^a , ix) $-(C_0$ -4alkyl)- CO - $N(R^a)(R^b)$, x) $-S(O)_{0-2}R^a$, xi) $-SO_2N(R^a)(R^b)$, xii) $-NR^aSO_2R^a$, xiii) $-C_1$ -10alkyl, and xiv) $-C_1$ -10alkyl, wherein one or more of the alkyl carbons can be replaced by a $-NR^a$ -, $-O$ -, $-S(O)_{1-2}$ -, $-O$ - $C(O)$ -, $-C(O)-O$ -, $-C(O)-N(R^a)$ -, $-N(R^a)-C(O)$ -, $-N(R^a)-C(O)-N(R^a)$ -, $-C(O)$ -, $-CH(OH)$ -, $-C=C$ -, or $-C\equiv C$ -;

(g) $-OCON(R^a)(R^b)$, or $-OSO_2N(R^a)(R^b)$;

30 (h) $-SH$, or $-SCON(R^a)(R^b)$;


(i) NO_2 ;

(j) NR^aR^b , $-N(COR^a)R^b$, $-N(SO_2R^a)R^b$, $-N(R^a)SO_2N(R^a)_2$, $-N(OR^a)CONR^aR^b$, $-N(R^a)SO_2R^a$ or $-N(R^a)CON(R^a)_2$;

(k) $-\text{CH}(\text{OR}^a)\text{R}^a$, $-\text{C}(\text{OR}^b)\text{CF}_3$, $-\text{CH}(\text{NHR}^b)\text{R}^a$, $-\text{C}(=\text{O})\text{R}^a$, $\text{C}(=\text{O})\text{CF}_3$, $-\text{SOCH}_3$, $-\text{SO}_2\text{CH}_3$, COOR^a , CN , CONR^aR^b , $-\text{COCONR}^a\text{R}^b$, $-\text{SO}_2\text{NR}^a\text{R}^b$, $-\text{CH}_2\text{O}-\text{SO}_2\text{NR}^a\text{R}^b$, $\text{SO}_2\text{N}(\text{R}^a)\text{OR}^a$, $-\text{C}(=\text{NH})\text{NH}_2$, $-\text{CR}^a=\text{N}-\text{OR}^a$, $\text{CH}=\text{CHCONR}^a\text{R}^b$;

(l) $-\text{CONR}^a(\text{CH}_2)_{0-2}\text{C}(\text{R}^a)(\text{R}^b)(\text{CH}_2)_{0-2}\text{CONR}^a\text{R}^b$;

- 5 (m) tetrazolyl, tetrazolinonyl, triazolyl, triazolinonyl, imidazolyl, imidazolonyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrazolonyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, or phenyl, any of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) $-\text{CN}$, iii) $-\text{NO}_2$, iv) $-\text{C}(=\text{O})\text{R}^a$, v) C_1-C_6 -alkyl, vi) $-\text{O}-\text{R}^a$, vii) $-\text{NR}^a\text{R}^b$, viii) $-\text{C}_0-\text{C}_4$ -alkyl - $\text{CO}-\text{O}-\text{R}^a$, ix) $-(\text{C}_0-\text{C}_4\text{-alkyl})-\text{NH}-\text{CO}-\text{OR}^a$, x) $-(\text{C}_0-\text{C}_4\text{-alkyl})-\text{CO}-\text{NR}^a\text{R}^b$, xi) $-\text{S}(\text{O})_{0-2}\text{R}^a$, xii) $-\text{SO}_2\text{NR}^a\text{R}^b$, xiii) $-\text{NHSO}_2\text{R}^a$, xiv) $-\text{C}_1-\text{C}_4$ -perfluoroalkyl, and xv) $-\text{O}-\text{C}_1-\text{C}_4$ -perfluoroalkyl;
- 10 (n) $-\text{C}(\text{R}^a)=\text{C}(\text{R}^b)-\text{COOR}^a$, or $-\text{C}(\text{R}^a)=\text{C}(\text{R}^b)-\text{CONR}^a\text{R}^b$;
- (o)



- 15 (p) piperidin-1-yl, morpholin-1-yl, pyrrolidin-1-yl, piperazin-1-yl or 4-substituted piperazin-1-yl, any of which is optionally substituted with 1-3 substituents selected from i) $-\text{CN}$, ii) $-\text{C}(=\text{O})(\text{R}^a)$, iii) C_1-C_6 -alkyl, iv) $-\text{OR}^a$, v) $-\text{NR}^a\text{R}^b$, vi) $-\text{C}_0-\text{C}_4$ -alkyl- $\text{CO}-\text{OR}^a$, vii) $-(\text{C}_0-\text{C}_4\text{-alkyl})-\text{NH}-\text{CO}-\text{OR}^a$, viii) $-(\text{C}_0-\text{C}_4\text{-alkyl})-\text{CON}(\text{R}^a)(\text{R}^b)$, ix) $-\text{SR}^a$, x) $-\text{S}(\text{O})_{0-2}\text{R}^a$, xi) $-\text{SO}_2\text{N}(\text{R}^a)(\text{R}^b)$, xii) $-\text{NR}^a\text{SO}_2\text{R}^a$, xiii) $-\text{C}_1-\text{C}_4$ -perfluoroalkyl and xiv) $-\text{O}-\text{C}_1-\text{C}_4$ -perfluoroalkyl;

R^a is

- (a) H;
- 25 (b) C_1-C_4 -alkyl, optionally substituted with one or more of the following substituents: F, CF_3 , OH, $\text{O}-(\text{C}_1-\text{C}_4\text{-alkyl})$, $\text{S}(\text{O})_{0-2}-(\text{C}_1-\text{C}_4\text{-alkyl})$, $-\text{OCONH}_2$, $-\text{OCONH}(\text{C}_1-\text{C}_4\text{-alkyl})$, $-\text{OCON}(\text{C}_1-\text{C}_4\text{-alkyl})(\text{C}_1-\text{C}_4\text{-alkyl})$, $-\text{OCONHC}_1-\text{C}_4\text{-alkyl-aryl}$, $-\text{OCON}(\text{C}_1-\text{C}_4\text{-alkyl})(\text{C}_1-\text{C}_4\text{-alkyl-aryl})$, NH_2 , $\text{NH}(\text{C}_1-\text{C}_4\text{-alkyl})$, $\text{N}(\text{C}_1-\text{C}_4\text{-alkyl})(\text{C}_1-\text{C}_4\text{-alkyl})$, $\text{NH}(\text{C}_1-\text{C}_4\text{-alkyl-aryl})$, $\text{N}(\text{C}_1-\text{C}_4\text{-alkyl})(\text{C}_1-\text{C}_4\text{-alkyl-aryl})$, NHCONH_2 , $\text{NHCONH}(\text{C}_1-\text{C}_4\text{-alkyl})$, $\text{NHCONH}(\text{C}_1-\text{C}_4\text{-alkyl-aryl})$, $-\text{NHCON}(\text{C}_1-\text{C}_4\text{-alkyl})(\text{C}_1-\text{C}_4\text{-alkyl})$, $\text{NHCON}(\text{C}_1-\text{C}_4\text{-alkyl})(\text{C}_1-\text{C}_4\text{-alkyl-aryl})$, $\text{N}(\text{C}_1-\text{C}_4\text{-alkyl})\text{CON}(\text{C}_1-\text{C}_4\text{-alkyl})(\text{C}_1-\text{C}_4\text{-alkyl})$, $\text{N}(\text{C}_1-\text{C}_4\text{-alkyl})\text{CON}(\text{C}_1-\text{C}_4\text{-alkyl})(\text{C}_1-\text{C}_4\text{-alkyl-aryl})$, $\text{COO}-(\text{C}_1-\text{C}_4\text{-alkyl})$, COOH , CN , CONH_2 , $\text{CONH}(\text{C}_1-\text{C}_4\text{-alkyl})$, $\text{CON}(\text{C}_1-\text{C}_4\text{-alkyl})(\text{C}_1-\text{C}_4\text{-alkyl})$, SO_2NH_2 , $\text{SO}_2\text{NH}(\text{C}_1-\text{C}_4\text{-alkyl})$, $\text{SO}_2\text{NH}(\text{C}_1-\text{C}_4\text{-alkyl-aryl})$, $\text{SO}_2\text{N}(\text{C}_1-\text{C}_4\text{-alkyl})(\text{C}_1-\text{C}_4\text{-alkyl})$, NHSO_2NH_2 , $-\text{C}(=\text{NH})\text{NH}_2$, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl;
- 30

(c) C₀-C₄-alkyl-(C₁-C₄)-perfluoroalkyl; or

(d) -C₁-C₄-alkyl-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO₂, iv) -C(=O)(C₁-C₄-alkyl), v) -O(C₁-C₄-alkyl), vi) -N(C₁-C₄-alkyl)(C₁-C₄-alkyl), vii) -C₁-10alkyl, and viii) -C₁-10alkyl, wherein one or more of the alkyl carbons can be replaced by a -O-, -S(O)₁₋₂-, -O-C(O)-, -C(O)-O-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C-;

R^b is

(a) H; or

(b) C₁-C₆-alkyl, optionally substituted with one or more of the following substituents: F, CF₃, OH, O-(C₁-C₄)alkyl, S(O)₀₋₂-(C₁-C₄)alkyl, -OCONH₂, -OCONH(C₁-C₄alkyl), NH₂, NH(C₁-C₄alkyl), N(C₁-C₄alkyl)(C₁-C₄alkyl), NHCONH₂, NHCONH(C₁-C₄alkyl), -NHCON(C₁-C₄alkyl)(C₁-C₄alkyl), COO-(C₁-C₄-alkyl), COOH, CN, or CONH₂;

R² is:

(a) H;

(b) -C₁-C₄-alkyl, -C₃-C₆-cycloalkyl or -C₁-C₄-alkyl-(C₃-C₆)-cycloalkyl, optionally substituted with one or more of the following substituents: F, CF₃, OH, O-(C₁-C₄)alkyl, S(O)₀₋₂-(C₁-C₄)alkyl, O-CONR^aR^b, NR^aR^b, N(R^a)CONR^aR^b, COO-(C₁-C₄)alkyl, COOH, CN, CONR^aR^b, SO₂NR^aR^b, N(R^a)SO₂NR^aR^b, -C(=NH)NH₂, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl;

(c) -C₀-C₄-alkyl-C₁-C₄-perfluoroalkyl;

(d) aryl or -(C₁-C₄-alkyl)-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO₂, iv) -C(=O)(R^a), v) -OR^a, vi) -NR^aR^b, vii) -C₀₋₄alkyl-CO-OR^a, viii) -(C₀₋₄alkyl)-NH-CO-OR^a, ix) -(C₀₋₄alkyl)-CO-N(R^a)(R^b), x) -S(O)₀₋₂R^a, xi) -SO₂N(R^a)(R^b), xii) -NR^aSO₂R^a, xiii) -C₁-10alkyl, and xiv) -C₁-10alkyl, wherein one or more of the alkyl carbons can be replaced by a -NR^a-, -O-, -S(O)₁₋₂-, -O-C(O)-, -C(O)-O-, -C(O)-N(R^a)-, -N(R^a)-C(O)-, -N(R^a)-C(O)-N(R^a)-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C-;

(e) -C(=O)(R^a), -CONR^aR^b, COO-(C₁-C₄)alkyl, -SO₂R^a, N(R^a)COR^a, -SO₂N(R^a)(R^b);

R³ is

(a) H;

- (b) -C₁-C₄-alkyl, -C₃-C₆-cycloalkyl or -C₁-C₄-alkyl-(C₃-C₆)-cycloalkyl, optionally substituted with one or more of the following substituents: F, CF₃, OH, O-(C₁-C₄)alkyl, S(O)₀₋₂-(C₁-C₄)alkyl, O-CONR^aR^b, NR^aR^b, N(R^a)CONR^aR^b, COO-(C₁-C₄)alkyl, COOH, CN, CONR^aR^b, SO₂NR^aR^b, N(R^a)SO₂NR^aR^b, -C(=NH)NH₂, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl;
- (c) -C₀-C₄-alkyl-C₁-C₄-perfluoroalkyl;
- (d) aryl or -(C₁-C₄-alkyl)-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO₂, iv) -C(=O)(R^a), v) -OR^a, vi) -NR^aR^b, vii) -C₀₋₄alkyl-CO-OR^a, viii) -(C₀₋₄alkyl)-NH-CO-OR^a, ix) -(C₀₋₄alkyl)-CO-N(R^a)(R^b), x) -S(O)₀₋₂R^a, xi) -SO₂N(R^a)(R^b), xii) -NR^aSO₂R^a, xiii) -C₁₋₁₀alkyl, and xiv) -C₁₋₁₀alkyl, wherein one or more of the alkyl carbons can be replaced by a -NR^a-, -O-, -S(O)₁₋₂-, -O-C(O)-, -C(O)-O-, -C(O)-N(R^a)-, -N(R^a)-C(O)-, -N(R^a)-C(O)-N(R^a)-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C-;
- (e) -O-C₁-C₄-alkyl, -O-C₀-C₄-alkyl-C₁-C₄-perfluoroalkyl, -O-aryl or -O(C₁-C₄-alkyl)-aryl;
- (f) -C(=O)(R^a), -SO₂R^a, -SO₂N(R^a)(R^b), CN, NR^aR^b, NO₂, F, Cl, Br, I, OH, OCONR^aR^b, O(C₁-C₄-alkyl)CONR^aR^b, -OSO₂NR^aR^b, COOR^a, N(R^a)COR^a, or CONR^aR^b;
- R⁴ and R⁵ each independently is:
- (a) H;
- (b) -C₁-C₆-alkyl, -C₂-C₆-alkenyl, -C₂-C₆-alkynyl or -C₃-C₆-cycloalkyl, any of which is optionally substituted with one or more of the following substituents: F, CF₃, -O-(C₁-C₄)alkyl, CN, -N(R^a)(R^b), -N(R^a)CO-(C₁-C₄)alkyl, COOR^b, CON(R^a)(R^b) or phenyl;
- (c) -O-C₀-C₆-alkyl, -O-aryl, or -O-C₁-C₄-alkyl-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO₂, iv) -C(=O)(R^a), v) -OR^a, vi) -NR^aR^b, vii) -C₀₋₄alkyl-CO-OR^a, viii) -(C₀₋₄alkyl)-NH-CO-OR^a, ix) -(C₀₋₄alkyl)-CO-N(R^a)(R^b), x) -S(O)₀₋₂R^a, xi) -SO₂N(R^a)(R^b), xii) -NR^aSO₂R^a, xiii) -C₁₋₁₀alkyl, and xiv) -C₁₋₁₀alkyl, wherein one or more of the alkyl carbons can be replaced by a -NR^a-, -O-, -S(O)₁₋₂-, -O-C(O)-, -C(O)-O-, -C(O)-N(R^a)-, -N(R^a)-C(O)-, -N(R^a)-C(O)-N(R^a)-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C-;
- (d) -C₀-C₄-alkyl-C₁-C₄-perfluoroalkyl, or -O-C₀-C₄-alkyl-C₁-C₄-perfluoroalkyl; or
- (e) CN, NH₂, NO₂, F, Cl, Br, I, OH, OCON(R^a)(R^b) O(C₁-C₄-alkyl)CONR^aR^b, -OSO₂N(R^a)(R^b), COOR^b, CON(R^a)(R^b), or aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted

with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO₂, iv) -C(=O)(R^a), v) -OR^a, vi) -NR^aR^b, vii) -C₀₋₄alkyl-CO-OR^a, viii) -(C₀₋₄alkyl)-NH-CO-OR^a, ix) -(C₀₋₄alkyl)-CO-N(R^a)(R^b), x) -S(O)₀₋₂R^a, xi) -SO₂N(R^a)(R^b), xii) -NR^aSO₂R^a, xiii) -C₁₋₁₀alkyl, and xiv) -C₁₋₁₀alkyl, wherein one or more of the alkyl carbons can be replaced by a -NR^a-, -O-, -S(O)₁₋₂-, -O-C(O)-, -C(O)-O-, -C(O)-N(R^a)-, -N(R^a)-C(O)-, -N(R^a)-C(O)-N(R^a)-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C-; and

R⁶, R⁷ and R⁸ each independently is:

(a) H;

(b) C₁-C₆-alkyl, C₂-C₄-alkenyl, C₂-C₄-alkynyl or C₃-C₆-cycloalkyl, any of which is optionally substituted with one or more of the following substituents: F, CF₃, OH, O-(C₁-C₄)alkyl, OCON(R^a)(R^b), NR^aR^b, COOR^a, CN, CONR^aR^b, N(R^a)CONR^aR^b, N(R^a)SO₂NR^aR^b, SO₂NR^aR^b, S(O)₀₋₂(C₁-C₄-alkyl), -C(=NH)NH₂, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl, or piperazinyl;

(c) -O-C₁-C₆-alkyl, -O-C₃-C₆-cycloalkyl, -S-C₁-C₆-alkyl or -S-C₃-C₆-cycloalkyl, any of which is optionally substituted with one or more of the following substituents: F, CF₃, OH, O-(C₁-C₄)alkyl, NH₂, NH(C₁-C₄-alkyl), N(C₁-C₄-alkyl)₂, COOH, CN, CONH₂, CONH(C₁-C₄-alkyl), CONH(C₁-C₄-alkyl)₂, SO₂NH₂, SO₂NH(C₁-C₄-alkyl), tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl, or piperazinyl;

(d) -C₀-C₄-alkyl-C₁-C₄-perfluoroalkyl, or -O-C₀-C₄-alkyl-C₁-C₄-perfluoroalkyl;

(e) -O-aryl, or -O-C₁-C₄-alkyl-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO₂, iv) -C(=O)(R^a), v) -OR^a, vi) -NR^aR^b, vii) -C₀₋₄alkyl-CO-OR^a, viii) -(C₀₋₄alkyl)-NH-CO-OR^a, ix) -(C₀₋₄alkyl)-CO-N(R^a)(R^b), x) -S(O)₀₋₂R^a, xi) -SO₂N(R^a)(R^b), xii) -NR^aSO₂R^a, xiii) -C₁₋₁₀alkyl, and xiv) -C₁₋₁₀alkyl, wherein one or more of the alkyl carbons can be replaced by a -NR^a-, -O-, -S(O)₁₋₂-, -O-C(O)-, -C(O)-O-, -C(O)-N(R^a)-, -N(R^a)-C(O)-, -N(R^a)-C(O)-N(R^a)-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C-; (f) CN, N(R^a)(R^b), NO₂, F, Cl, Br, I, -OR^a, -SR^a, -OCON(R^a)(R^b), -OSO₂N(R^a)(R^b), COOR^b, CON(R^a)(R^b), -N(R^a)CON(R^a)(R^b), -N(R^a)SO₂N(R^a)(R^b), -C(OR^b)R^a, -C(OR^a)CF₃, -C(NHR^a)CF₃, -C(=O)R^a, C(=O)CF₃, -SOCH₃, -SO₂CH₃, -NHSO₂(C₁₋₆-alkyl), -NHSO₂-aryl, SO₂N(R^a)(R^b), -CH₂OSO₂N(R^a)(R^b), SO₂N(R^b)-OR^a, -C(=NH)NH₂, -CR_a=N-OR_a, CH=CH or aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected

from i) F, Cl, Br, I, ii) -CN, iii) -NO₂, iv) -C(=O)(R^a), v) -OR^a, vi) -NR^aR^b, vii) -C₀₋₄alkyl-CO-OR^a,
 viii) -(C₀₋₄alkyl)-NH-CO-OR^a, ix) -(C₀₋₄alkyl)-CO-N(R^a)(R^b), x) -S(O)₀₋₂R^a, xi) -SO₂N(R^a)(R^b),
 xii) -NR^aSO₂R^a, xiii) -C₁₋₁₀alkyl, and xiv) -C₁₋₁₀alkyl, wherein one or more of the alkyl carbons
 can be replaced by a -NR^a-, -O-, -S(O)₁₋₂-, -O-C(O)-, -C(O)-O-, -C(O)-N(R^a)-, -N(R^a)-C(O)-, -
 5 N(R^a)-C(O)-N(R^a)-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C-; or when R⁶ and R⁷ are present on adjacent
 carbon atoms, R⁶ and R⁷, together with the ring to which they are attached, may form a bicyclic
 aromatic ring selected from naphthyl, indolyl, quinoliny, isoquinoliny, quinoxaliny, benzofuryl,
 benzothienyl, benzoxazolyl, benzothiazolyl, and benzimidazolyl, any aromatic ring of which is
 optionally substituted with 1-4 independent substituents selected from i) halogen, ii) -CN, iii) -NO₂,
 10 iv) -CHO, v) -O-C₁₋₄alkyl, vi) -N(C₀₋₄alkyl)(C₀₋₄alkyl), vii) -C₀₋₄alkyl-CO-O(C₀₋₄alkyl), viii)
 -(C₀₋₄alkyl)-NH-CO-O(C₀₋₄alkyl), ix) -(C₀₋₄alkyl)-CO-N(C₀₋₄alkyl)(C₀₋₄alkyl), x) -S(C₀₋₄alkyl),
 xi) -S(O)(C₁₋₄alkyl), xii) -SO₂(C₀₋₄alkyl), xiii) -SO₂N(C₀₋₄alkyl)(C₀₋₄alkyl), xiv) -NHSO₂(C₀₋₄
 15 4alkyl)(C₀₋₄alkyl), xv) -C₁₋₁₀alkyl and xvi) -C₁₋₁₀alkyl in which one or more of the carbons can be
 replaced by a -N(C₀₋₆alkyl)-, -O-, -S(O)₁₋₂-, -O-C(O)-, -C(O)-O-, -C(O)-N(C₀₋₆alkyl)-, -N(C₀₋₆
 6alkyl)-C(O)-, -N(C₀₋₆alkyl)-C(O)-N(C₀₋₆alkyl)-, -C(O)-, -CH(OH), -C=C-, or -C≡C-.

2. The compound according to Claim 1 represented by Formula (I), or a
 pharmaceutically acceptable salt thereof.

20 3. The compound according to Claim 2, or a pharmaceutically acceptable salt
 thereof, wherein

R⁶ is other than H and is attached at the ortho position.

25 4. The compound according to Claim 1 represented by Formula (II), or a
 pharmaceutically acceptable salt thereof.

5. The compound according to Claim 4, or a pharmaceutically acceptable salt
 thereof, wherein


30 R⁶ is other than H and is attached at the ortho position.

6. The compound according to Claim 1 represented by Formula (III), or a
 pharmaceutically acceptable salt thereof.

7. The compound according to Claim 6, or a pharmaceutically acceptable salt thereof, wherein

HET is


5



8. The compound according to Claim 6, or a pharmaceutically acceptable salt thereof, wherein

10


HET is



9. The compound according to Claim 6, or a pharmaceutically acceptable salt thereof, wherein

15

HET is




20

10. The compound according to Claim 6 or a pharmaceutically acceptable salt thereof, wherein


25

HET is



11. The compound according to Claim 6, or a pharmaceutically acceptable salt thereof, wherein

HET is




12. The compound according to Claim 6, or a pharmaceutically acceptable salt thereof, wherein

R⁶ is other than H and is attached at the ortho position.

13. The compound according to Claim 1 represented by Formula (IV), or a pharmaceutically acceptable salt thereof.


14. The compound according to Claim 13, or a pharmaceutically acceptable salt thereof, wherein

HET is




15. The compound according to Claim 13, or a pharmaceutically acceptable salt thereof, wherein

HET is




16. The compound according to Claim 13, or a pharmaceutically acceptable salt thereof, wherein

HET is




17. The compound according to Claim 13, or a pharmaceutically acceptable salt thereof, wherein

HET is



18. The compound according to Claim 13, or a pharmaceutically acceptable salt thereof, wherein


HET is



19. The compound according to Claim 13, or a pharmaceutically acceptable salt thereof, wherein

R⁶ is other than H and is attached at the ortho position.


20. A compound represented by





or a pharmaceutically acceptable salt thereof.


5

21. The compound according to Claim 1 represented by



R ⁶	R ⁷	R ⁶	R ⁴	R ³	R ¹
H	H	CF ₃	H	H	CH ₃
H	H	OCF ₃	H	H	CH ₃
H	H	OCF ₃	H	CH ₃	H
H	H	CF ₃	H	CH ₃	H
H	H	CF ₃	H	CH ₃	CH ₃
H	H	OCF ₃	H	CH ₃	CH ₃
H	H	Cl	H	H	CF ₃
H	H	Cl	H	CH ₃	CONH ₂
H	H	CF ₃	H	CH ₃	CONH ₂
H	H	CF ₃	H	CH ₃	COOCH ₃
H	H	CF ₃	H	CH ₃	COOH

H	H	Cl	H	t-Bu	COOH
H	H	OCF ₃	H	CH ₃	COOCH ₃
H	H	OCF ₃	H	CH ₃	CONH ₂
H	H	OCF ₃	H	CH ₃	COOH
H	H	OCF ₃	H	COOEt	CH ₃
H	H	CF ₃	H	COOEt	CH ₃
H	H	OCF ₃	H	COOH	CH ₃
H	H	CF ₃	H	COOH	CH ₃
H	H	OH	H	CH ₃	CONH ₂
H	H	O-Ph	H	CH ₃	COOH
H	H	O-Ph	H	CH ₃	COOMe
H	H	O-Ph	H	CH ₃	COOEt
H	H	O-Ph	H	CH ₃	CONH ₂
H	H	CHO	H	CH ₃	CONH ₂
H	4-Cl	Cl	H	CH ₃	CONH ₂
H	4-CF ₃	H	H	CH ₃	CONH ₂
H	3-CF ₃	H	H	CH ₃	CONH ₂
5-Cl	3-Cl	H	H	CH ₃	CONH ₂
H	3-F	H	H	CH ₃	CONH ₂
5-CF ₃	3-CF ₃	H	H	CH ₃	CONH ₂
4-F	3-Cl	H	H	CH ₃	CONH ₂
H	4-Cl	H	H	CH ₃	CONH ₂
H	4-F	H	H	CH ₃	CONH ₂
4-Cl	3-Cl	H	H	CH ₃	CONH ₂
H	3-OCH ₃	OCH ₃	H	CH ₃	CONH ₂
H	3-Cl	CH ₃	H	CH ₃	CONH ₂
H	5-Cl	OCH ₃	H	CH ₃	CONH ₂
H	H		H	CH ₃	CONH ₂
H		H	H	CH ₃	CONH ₂
H	3-Ph	H	H	CH ₃	CONH ₂


H	H		H	CH ₃	CONH ₂
H	4-CH ₂ OH	H	H	CH ₃	CONH ₂
H	H	H	H	CH ₃	CONH ₂
H	H	CH ₃	H	CH ₃	CONH ₂
H	3-COOH	CH ₃	H	CH ₃	CONH ₂
H	3-F	CH ₃	H	CH ₃	CONH ₂
H	4-OPh	H	H	CH ₃	CONH ₂
H	3-Cl	H	H	CH ₃	CONH ₂
H	3-OEt	H	H	CH ₃	CONH ₂
H	H	F	H	CH ₃	CONH ₂
H	4-OEt	H	H	CH ₃	CONH ₂
H	6-F	F	H	CH ₃	CONH ₂
H	6-CH ₃	CH ₃	H	CH ₃	CONH ₂
H	4-t-Bu	H	H	CH ₃	CONH ₂
H	4-OCF ₃	H	H	CH ₃	CONH ₂
H	4-COCH ₃	H	H	CH ₃	CONH ₂
H	3-COCH ₃	H	H	CH ₃	CONH ₂
H	3-CH ₃	CH ₃	H	CH ₃	CONH ₂
H	4-COOH	H	H	CH ₃	CONH ₂
H	4-CHO	H	H	CH ₃	CONH ₂
H	4-CF ₃	CF ₃	H	CH ₃	CONH ₂
H	6-CF ₃	CF ₃	H	CH ₃	CONH ₂
H	6-F	CF ₃	H	CH ₃	CONH ₂
H	5-F	CF ₃	H	CH ₃	CONH ₂
H	4-Cl	CF ₃	H	CH ₃	CONH ₂
H	3-Cl	Cl	H	CH ₃	CONH ₂
H	H	OCH ₂ CF ₃	H	CH ₃	CONH ₂
H	H	OCF ₃	F	CH ₃	COOEt
H	H	OCF ₃	F	CH ₃	CONH ₂
H	H	OCF ₃	F	COOEt	CH ₃
H	H	OCF ₃	F	CONH ₂	CH ₃
H	3-Cl	Cl	F	CH ₃	CONH ₂

H	4-CF ₃	CF ₃	F	CH ₃	CONH ₂
H	H	OCF ₃	F	CH ₃	COOH
H	5-F	OH	H	CH ₃	CONH ₂
H	5-NMe ₂	OCF ₃	H	CH ₃	CONH ₂
H	4-F	CF ₃	H	CH ₃	COOH
H	4-CF ₃	CF ₃	H	CH ₃	COOH
H	4-CF ₃	F	H	CH ₃	COOH
H	3-CF ₃	CF ₃	H	CH ₃	COOH
H	H	OCF ₃	H	CH ₃	CF ₃
H	H	OCF ₃	H	t-Bu	CONH ₂
H	H	OCF ₃	H	OCH ₂ CH ₃	CH ₃
H	5-F	CF ₃	H	CH ₃	COOH
H	3-Cl	Cl	H	CH ₃	COOH
H	4-Cl	CF ₃	H	CH ₃	COOH
H	3-Cl	Cl	F	CH ₃	COOH
H	6-Cl	Cl	H	CH ₃	COOH
H	6-Cl	Cl	H	CH ₃	CONH ₂
H	6-F	CF ₃	H	CH ₃	COOH
H	H	CF ₃	H	CH ₃	COOH
H	6-CF ₃	CF ₃	H	CH ₃	COOH
H	6-Cl	CF ₃	H	CH ₃	CONH ₂


or a pharmaceutically acceptable salt thereof.

22. The compound of Claim 1 represented by

5















R ⁶	R ³	R ²	R ¹
Cl	H	CONH-t-Bu	H
Cl	H	CONH-Me	H
Cl	H		H

Cl	H		H
CF ₃	H	COOEt	NH ₂
CF ₃	H	COOH	H
OCF ₃	H	COOEt	H
OCF ₃	H	COOH	NH ₂

or a pharmaceutically acceptable salt thereof.


23. A compound represented by

5


or a pharmaceutically acceptable salt thereof.

24. A compound represented by



or a pharmaceutically acceptable salt thereof.


25. A compound represented by



5

or a pharmaceutically acceptable salt thereof.

26. The compound of Claim 1 is represented by





5

R^a	R^b
$-\text{CH}_2\text{CH}_2\text{OH}$	H
$-\text{CH}_2\text{CH}_2\text{CH}_2\text{OH}$	H
$-\text{CH}(\text{CH}_2\text{OH})_2$	H
$-\text{CH}_3$	H
$-\text{CH}_2\text{CH}_3$	H
	H
	H
	H
	H
	H
	H
	H
	CH ₃
	CH ₃
	H

or a pharmaceutically acceptable salt thereof.


27. A compound represented by





or a pharmaceutically acceptable salt thereof.

5 28. The compound of Claim 1 represented by



R ⁷	R ⁶	R ⁴	R ³	R ²	R ¹
H	CF ₃	H	CONH ₂	H	CONH ₂
H	OCF ₃	H	CONH ₂	H	CONH ₂
4-CF ₃	CF ₃	H	CONH ₂	H	CONH ₂
5-F	CF ₃	H	CONH ₂	H	CONH ₂
5-CF ₃	OCF ₃	H	CONH ₂	H	CONH ₂
H	OCHF ₂	H	CONH ₂	H	CONH ₂
5-CF ₃	CF ₃	H	CONH ₂	H	CONH ₂
6-F	CF ₃	H	CONH ₂	H	CONH ₂
4-F	OCH ₂ CF ₃ CF ₃	H	CONH ₂	H	CONH ₂


6-CF ₃	CF ₃	H	CONH ₂	H	CONH ₂
H	OCH(CH ₃) ₂	H	CONH ₂	H	CONH ₂
3-OCF ₃	OCH ₂ CF ₃ CF ₃	H	CONH ₂	H	CONH ₂
3-CF ₃	OCH ₂ CF ₃ CF ₃	H	CONH ₂	H	CONH ₂
5-F	OCH ₂ CF ₃ CF ₃	H	CONH ₂	H	CONH ₂
5-F	OCF ₃	H	CONH ₂	H	CONH ₂
4-F	CF ₃	H	CONH ₂	H	CONH ₂
H	CF ₃	H	CONH-Et	H	CONH-Et
H	CF ₃	H	CONH ₂	H	CONH-Et
H	OCF ₃	4-F	CONH ₂	H	CONH ₂
H	OCF ₃	H	CONH-Et	H	CONH ₂
H	OCF ₃	H	COOEt	H	COOEt
H	CF ₃	H	COOEt	H	COOEt
H	OCF ₃	H	COOEt	H	CONH ₂
H	CF ₃	H	COOEt	H	CONH ₂
4-CF ₃	CF ₃	H	COOEt	H	CONH ₂
4-CF ₃	CF ₃	H	CONH ₂	H	COOEt
H	OCF ₃	H	CONH ₂	H	COOEt
H	CF ₃	H	CONH ₂	H	COOEt
H	OCF ₃	4-F	COOH	H	COOEt
H	OCF ₃	4-F	COOH	H	CONH ₂
H	OCF ₃	4-F	CONH ₂	H	COOEt
H	OCF ₃	H	COOH	H	CONH ₂
H	OCF ₃	H	CH ₃	COOMe	COOEt
H	OCF ₃	H	CH ₃	COOH	COOH
4-CF ₃	CF ₃	H	CH ₃	COOH	COOH
H	OCF ₃	H	CH ₃	CONH ₂	CONH ₂
4-CF ₃	CF ₃	H	CH ₃	CONH ₂	CONH ₂
H	CF ₃	H	CH ₃	COOH	COOH
H	CF ₃	H	CH ₃	CONH ₂	CONH ₂
5-CF ₃	CF ₃	H	CH ₃	CONH ₂	CONH ₂
5-CF ₃	CF ₃	H	CH ₃	COOH	COOH
H	CF ₃	4-OCF ₃	CH ₃	COOMe	COOH
H	OCF ₃	4-OCF ₃	CH ₃	CONH ₂	CONH ₂

H	CF ₃	4-OCF ₃	CH ₃	CONH ₂	CONH ₂
H	OCF ₃	4-F	CH ₃	COOEt	COOEt
H	CF ₃	4-F	CH ₃	COOEt	COOEt
H	OCF ₃	4-F	CH ₃	COOEt	CONH ₂
H	OCF ₃	4-F	CH ₃	CONH ₂	CONH ₂
H	CF ₃	4-F	CH ₃	COOEt	CONH ₂
H	CF ₃	4-F	CH ₃	CONH ₂	CONH ₂
H	OCF ₃	4-F	CH ₃	COOH	COOH
H	Cl	H	H	CONH-Me	H
H	Cl	H	H	CONH ₂	CF ₃
H	OCF ₃	H	H	COOEt	NH ₂
H	CF ₃	H	H	COOEt	NH ₂
H	OCF ₃	H	H	COOH	H
H	OCF ₃	H	H	COOEt	H
4-CF ₃	CF ₃	H	H	COOEt	NH ₂
H	OCF ₃	H	H	COOH	NH ₂
H	OCF ₃	H	H	CONH ₂	H
H	OCF ₃	H	H	CONH ₂	NH ₂
H	OCF ₃	H	CH ₃	CONH ₂	CH ₃
H	Cl	H	H	CONH ₂	H


or a pharmaceutically acceptable salt thereof.

29. The compound of Claim 1 represented by

5



R ⁷	R ⁶	R ⁴	R ³	R ²	R ¹
H	OCF ₃	H	H	COOCH ₃	H

H	CF ₃	H	NH ₂	CONH ₂	H
H	OCF ₃	H	NH ₂	COOH	H
H	OCF ₃	H	NH ₂	CONH ₂	H
H	CF ₃	H	NH ₂	COOH	H
H	OCF ₃	H	H	COOEt	H
H	CF ₃	H	H	COOEt	H
H	CF ₃	H	H	CONH ₂	
H	OCF ₃	F	H	COOEt	H
H	OCF ₃	F	H	CONH ₂	H
H	OCF ₃	H	CH ₃	COOEt	H
H	OCF ₃	H	CH ₃	COOH	H
H	OCF ₃	H	CH ₃	CONH ₂	H
H	CF ₃	H	CH ₃	COOH	H
H	CF ₃	H	CH ₃	CONH ₂	H
4-CF ₃	CF ₃	H	CH ₃	COOH	H
4-CF ₃	CF ₃	H	CH ₃	CONH ₂	H
H	OCF ₃	F	H	COOH	H
5-CF ₃	CF ₃	H	H	COOH	H
5-CF ₃	CF ₃	H	H	CONH ₂	H
H	CF ₃	H	CH ₃	CONH ₂	t-Bu
H	OCF ₃	H	H	COOH	t-Bu
H	OCF ₃	H	H	CONH ₂	t-Bu
6-F	CF ₃	H	H	CONH ₂	H
6-F	CF ₃	H	H	COOH	H
5-F	OCF ₃	H	H	COOH	H
5-F	OCF ₃	H	H	CONH ₂	H
4-CF ₃	CF ₃	H	H	CONH ₂	H
H	OCF ₃	H	H	CONHNMe ₂	H

or a pharmaceutically acceptable salt thereof.

30. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

5 31. The pharmaceutical composition according to Claim 27, further comprising a second therapeutic agent selected from the group consisting of: i) opiate agonists, ii) opiate antagonists, iii) calcium channel antagonists, iv) 5HT receptor agonists, v) 5HT receptor antagonists vi) sodium channel antagonists, vii) NMDA receptor agonists, viii) NMDA receptor antagonists, ix) COX-2 selective inhibitors, x) NK1 antagonists, xi) non-steroidal anti-inflammatory drugs, xii) selective serotonin
10 reuptake inhibitors, xiii) selective serotonin and norepinephrine reuptake inhibitors, xiv) tricyclic antidepressant drugs, xv) norepinephrine modulators, xvi) lithium, xvii) valproate, and xviii) neurontin.

32. A method of treatment or prevention of pain comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of
15 the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

33. A method of treatment of chronic, visceral, inflammatory and neuropathic pain syndromes comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a
20 pharmaceutically acceptable salt thereof.

34. A method of treatment of pain resulting from, or associated with, traumatic nerve injury, nerve compression or entrapment, postherpetic neuralgia, trigeminal neuralgia, diabetic neuropathy, cancer and chemotherapy, comprising the step of administering to a patient in need thereof a
25 therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

35. A method of treatment of chronic lower back pain comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically
30 effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

36. A method of treatment of phantom limb pain comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically
35 effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

37. A method of treatment of HIV- and HIV treatment-induced neuropathy, chronic pelvic pain, neuroma pain, complex regional pain syndrome, chronic arthritic pain and related neuralgias comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

38. A method of administering local anesthesia comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

39. A method of treatment of irritable bowel syndrome and Crohn's disease comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

40. A method of treatment of epilepsy and partial and generalized tonic seizures comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

41. A method for neuroprotection under ischaemic conditions caused by stroke or neural trauma comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

42. A method of treatment of multiple sclerosis comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

43. A method of treatment of bipolar disorder comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

44. A method of treatment of tachy-arrhythmias comprising the step of administering to a patient in need thereof a therapeutically effective amount, or a prophylactically effective amount, of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof.